{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:31:39Z","timestamp":1791613899660,"version":"4.3.4"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Lung Cancer Initiative of North Carolina"},{"name":"East Carolina University Coach Rock Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0648-3","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T12:02:49Z","timestamp":1562328169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7622-720X","authenticated-orcid":false,"given":"Abdul Rafeh","family":"Naqash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Appah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li V.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahvish","family":"Muzaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Marie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin D.","family":"Mccallen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravanti","family":"Macherla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darla","family":"Liles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"issue":"6382","key":"648_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science."},{"key":"648_CR2","doi-asserted-by":"publisher","unstructured":"Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1538 .","DOI":"10.1158\/1078-0432.CCR-18-1538"},{"issue":"19","key":"648_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"7","key":"648_CR4","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez\u2013Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"key":"648_CR5","doi-asserted-by":"publisher","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019. https:\/\/doi.org\/10.1038\/s41571-019-0218-0 .","DOI":"10.1038\/s41571-019-0218-0"},{"issue":"2","key":"648_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"key":"648_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","volume":"103","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7\u201316.","journal-title":"Eur J Cancer"},{"issue":"5","key":"648_CR8","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","volume":"24","author":"EJ Davis","year":"2019","unstructured":"Davis EJ, Salem JE, Young A, Green JR, Ferrell PB, Ancell KK, et al. Hematologic complications of immune checkpoint inhibitors. Oncologist. 2019;24(5):584\u20138.","journal-title":"Oncologist."},{"issue":"1","key":"648_CR9","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","volume":"6","author":"N Delanoy","year":"2019","unstructured":"Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6(1):e48\u201357.","journal-title":"Lancet Haematol"},{"issue":"3","key":"648_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CJI.0b013e31819aa40b","volume":"32","author":"M Akhtari","year":"2009","unstructured":"Akhtari M, Waller EK, Jaye DL, Lawson DH, Ibrahim R, Papadopoulos NE, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009;32(3):322\u20134.","journal-title":"J Immunother"},{"issue":"3","key":"648_CR11","doi-asserted-by":"publisher","first-page":"232470961666183","DOI":"10.1177\/2324709616661835","volume":"4","author":"Makiko Ban-Hoefen","year":"2016","unstructured":"Ban-Hoefen M, Burack R, Sievert L, Sahasrabudhe D. Ipilimumab-induced neutropenia in melanoma. J Investig Med High Impact Case Rep. 2016;4(3). https:\/\/doi.org\/10.1177\/2324709616661835 .","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"key":"648_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2016.06.026","volume":"99","author":"S Tabchi","year":"2016","unstructured":"Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer. 2016;99:123\u20136.","journal-title":"Lung Cancer"},{"issue":"3","key":"648_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000377650","volume":"38","author":"S Wozniak","year":"2015","unstructured":"Wozniak S, Mackiewicz-Wysocka M, Krokowicz L, Kwinta L, Mackiewicz J. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report. Oncol Res Treat. 2015;38(3):105\u20138.","journal-title":"Oncol Res Treat"},{"issue":"8","key":"648_CR14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/CAD.0000000000000661","volume":"29","author":"A Barbacki","year":"2018","unstructured":"Barbacki A, Maliha PG, Hudson M, Small D. A case of severe Pembrolizumab-induced neutropenia. Anti-Cancer Drugs. 2018;29(8):817\u20139.","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"648_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/CJI.0000000000000194","volume":"41","author":"Y Sun","year":"2018","unstructured":"Sun Y, Lee SK, Oo TH, Rojas-Hernandez CM. Management of immune-mediated Cytopenias in the era of cancer immunotherapy: a report of 4 cases. J Immunother. 2018;41(1):32\u20134.","journal-title":"J Immunother"},{"issue":"8","key":"648_CR16","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1200\/JOP.18.00177","volume":"14","author":"N Meti","year":"2018","unstructured":"Meti N, Petrogiannis-Haliotis T, Esfahani K. Refractory neutropenia secondary to dual immune checkpoint inhibitors that required second-line immunosuppression. J Oncol Pract. 2018;14(8):514\u20136.","journal-title":"J Oncol Pract"},{"issue":"7","key":"648_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","volume":"28","author":"I Turgeman","year":"2017","unstructured":"Turgeman I, Wollner M, Hassoun G, Bonstein L, Bar-Sela G. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anti-Cancer Drugs. 2017;28(7):811\u20134.","journal-title":"Anti-Cancer Drugs"},{"issue":"12","key":"648_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","volume":"6","author":"A Young","year":"2018","unstructured":"Young A, Quandt Z, Bluestone JA. The balancing act between cancer immunity and autoimmunity in response to immunotherapy. Cancer Immunol Res. 2018;6(12):1445\u201352.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"648_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40425-019-0533-0","volume":"7","author":"S Rapisuwon","year":"2019","unstructured":"Rapisuwon S, Izar B, Batenchuk C, Avila A, Mei S, Sorger P, et al. Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):61.","journal-title":"J Immunother Cancer"},{"key":"648_CR20","doi-asserted-by":"publisher","unstructured":"Berner F, Bomze D, Diem S, Ali OH, F\u00e4ssler M, Ring S, et al. Association of checkpoint inhibitor\u2013induced toxic effects with shared cancer and tissue antigens in non\u2013small cell lung cancer. JAMA Oncol. 2019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.0402 .","DOI":"10.1001\/jamaoncol.2019.0402"},{"issue":"2","key":"648_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715\u201320.","journal-title":"J Clin Invest"},{"issue":"17","key":"648_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"issue":"7","key":"648_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1634\/theoncologist.2017-0531","volume":"23","author":"S Parakh","year":"2018","unstructured":"Parakh S, Cebon J, Klein O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy. Oncologist. 2018;23(7):849\u201351.","journal-title":"Oncologist."},{"issue":"9","key":"648_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","volume":"154","author":"LL Wang","year":"2018","unstructured":"Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, et al. Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol. 2018;154(9):1057\u201361.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"648_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, et al. PD-1 blockade expands Intratumoral memory T cells. Cancer Immunol Res. 2016;4(3):194\u2013203.","journal-title":"Cancer Immunol Res"},{"issue":"19","key":"648_CR26","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167\u201375.","journal-title":"J Clin Oncol"},{"issue":"10","key":"648_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/17425255.2016.1216976","volume":"12","author":"TC Longoria","year":"2016","unstructured":"Longoria TC, Tewari KS. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Expert Opin Drug Metab Toxicol. 2016;12(10):1247\u201353.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"648_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with Nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4(3):374\u20138.","journal-title":"JAMA Oncol"},{"issue":"11","key":"648_CR29","doi-asserted-by":"publisher","first-page":"S1559","DOI":"10.1016\/j.jtho.2017.09.027","volume":"12","author":"AR Naqash","year":"2017","unstructured":"Naqash AR, Stroud CRG, Cherry C, Muzaffar M, Bowling M, Walker PR. 4A.03 predictive utility of c-reactive protein (CRP) in advanced stage lung cancer treated with anti-programmed cell death-1 (PD-1) therapy: topic: medical oncology. J Thorac Oncol. 2017;12(11):S1559.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"648_CR30","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/0284186X.2017.1406668","volume":"57","author":"AR Naqash","year":"2018","unstructured":"Naqash AR, Yang LV, Sanderlin EJ, Atwell DC, Walker PR. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncol. 2018;57(5):705\u20138.","journal-title":"Acta Oncol"},{"issue":"1","key":"648_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","volume":"120","author":"S Khan","year":"2019","unstructured":"Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, et al. Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer. 2019;120(1):63\u20138.","journal-title":"Br J Cancer"},{"issue":"3","key":"648_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/1078155217745144","volume":"25","author":"CR Stroud","year":"2019","unstructured":"Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25(3):551\u20137.","journal-title":"J Oncol Pharm Pract"},{"issue":"19","key":"648_CR33","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1\u2013targeted therapy in lung cancer patients. Proc Natl Acad Sci. 2017;114(19):4993\u20138.","journal-title":"Proc Natl Acad Sci"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0648-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0648-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T00:41:26Z","timestamp":1663893686000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0648-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["648"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0648-3","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Appropriate consent for conducting and reporting patient biomarker data presented in this manuscript was obtained from the ECU IRB (IRB 16\u2013000719).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Individual patient consent was not applicable as no information in this article including the images, can be categorized as identifiable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}